





Dkt. 67705/JPW/GJG/MML/SK

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Eran Blaugrund et al.

Serial No. : 10/712,958

Filed: November 13, 2003

FOR : USE OF RASAGILINE WITH OR WITHOUT RILUZOLE TO

TREAT AMYOTROPHIC LATERAL SCLEROSIS

1185 Avenue of the Americas

New York, New York 10036

September 7, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following documents which are listed on Form PTO-1449 (Exhibit A) and are also listed below.

Pursuant to the Notice appearing in the August 5, 2003 Official Gazette, because this application was filed after June 30, 2003, copies of the U.S. Patents and U.S. Patent Application Publications listed herein are not provided.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Thus, this Information Disclosure Statement should be entered and considered. Copies of the documents listed below as items 14-37 are attached hereto as

Serial No.: 10/712,958

Filed: November 13, 2003

Page 2

Exhibits 1-21. A copy of items 33, 34 and 36 will be forwarded in due course.

Items 16 and 27 below were cited in the June 16, 2004 International Search Report issued in Connection with PCT International Application No. PCT/US03/36288 which is related to the subject application. A copy of the International Search Report is enclosed as **Exhibit B**.

- 1. U.S. Patent No. 5,387,612, issued February 7, 1995 to Youdim, et al.;
- 2. U.S. Patent No. 5,453,446, issued September 26, 1995 to Youdim, et al.;
- 3. U.S. Patent No. 5,457,133, issued October 10, 1995 to Youdim, et al.;
- 4. U.S. Patent No. 5,668,181, issued September 16, 1997 to Youdim, et al.;
- 5. U.S. Patent No. 5,576,353, issued November 19, 1996 to Youdim, et al.;
- 6. U.S. Patent No. 5,532,415, issued July 2, 1996 to Youdim, et al.;

Serial No.: 10/712,958

Filed: November 13, 2003

- 7. U.S. Patent No. 5,599,991, issued February 4, 1997 to Youdim, et al.;
- 8. U.S. Patent No. 5,786,390, issued July 28, 1998 to Youdim, et al.;
- 9. U.S. Patent No. 5,519,061, issued May 21, 1996 to Youdim, et al.;
- 10. U.S. Patent No. 5,891,923, issued April 6, 1999 to Youdim, et al.;
- 11. U.S. Patent No. 5,744,500, issued April 28, 1998 to Youdim, et al.;
- 12. U.S. Patent No. 6,316,504, issued February 7, 1995 to Youdim, et al.;
- 13. U.S. Patent Application Publication No. 2004/0010038 A1, published on January 15, 2004;
- 14. PCT International Application No. PCT/US03/05871 filed February 27, 2003, International Publication No. WO 2003/072055 A2 published September 4, 2003 (Exhibit 1);
- 15. PCT International Application No. PCT/US03/036288 filed November 13, 2003, International Publication No. WO 2004/045515 A2 published June 3, 2004 (Exhibit 2);

Serial No.: 10/712,958

Filed: November 13, 2003

- 16. Bensimon G, et al., (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med., 330(9):585-91 (Exhibit 3)
- 17. Bentué-Ferrer D, et al., (1996) Monoamine Oxidase B
  Inhibitors. CNS Drugs., 6(3):217-36 (Exhibit 4)
- 18. Doble A. (1996) The pharmacology and mechanism of action riluzole. Neurology, 47 (Suppl. 1):S233-41 (Exhibit 5);
- 19. Eliash S, et al. (2001) "Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J.

  Neural Transm., 108:909-23 (Exhibit 6);
- 20. Ferrante RJ, et al., (1997) Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. <a href="Ann. Neurol.">Ann. Neurol.</a>, 42:326-34 (Exhibit 7);
- "Guidance for Industry: In vivo drug metabolism/drug interaction studies study design, data analysis, and recommendations for dosing and labeling," U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), November 1999 (Exhibit 8);

Serial No.: 10/712,958

Filed: November 13, 2003

- 22. Gurney ME, et al., (1994) Motor neuron degeneration in mice that express a human superoxide dismutase mutation. Science, 264:1772-5 (Exhibit 9);
- 23. Gurney ME, et al., (1996) Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. <a href="Ann. Neurol.">Ann. Neurol.</a>, 39:147-57 (Exhibit 10);
- 24. Huang W, et al., (1999) Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. <a href="Eur. J.Pharmacol."><u>Eur. J. Pharmacol.</u></a>, 336:127-35 (**Exhibit 11**);
- 25. Kong J, et al., (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci., 18:3241-50 (Exhibit 12);
- 26. Lacomblez L, et al., (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. <u>Lancet</u>, 347:1425-31 (Exhibit 13);
- 27. Lange DJ, et al., (1998) Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. <u>Arch Neurol.</u>, 55(1):93-6 (Exhibit 14);

Serial No.: 10/712,958

Filed: November 13, 2003

- 28. Ludolph AC, et al., (1999) Antiglutamate therapy in ALS which is the next step? <u>J. Neural Transm.</u>, 55(Suppl.):79-96 (Exhibit 15);
- 29. Maruyama W, et al., (2000) Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)-and (S)-aminoindan, rasagiline and TV1022. J. Neural Transm., 60(Suppl):171-86. (Exhibit 16);
- 30. Maruyama W, et al. (2001) Transfection-enforced bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J. Neurochem., 78:727-35 (Exhibit 17);
- 31. Physicians Desk Reference (2002), p. 772-5 (Exhibit 18)
- 32. Speiser Z, et al., (1999) Studies with rasagiline, a monamine oxidase-B inhibitor, in experimental focal ischemia in the rat. <u>J. Neural Transm.</u>, 106:593-606 (Exhibit 19);
- 33. Traynor BJ, et al., (2001) Riluzole and prognosis in amyotrophic lateral sclerosis: Findings of the Irish amyotrophic lateral sclerosis register over a five year study period 1995-2000. ALS and Other Motor Neuron Disorders, 2(Suppl. 2):43-4;

Serial No.: 10/712,958

Filed: November 13, 2003

Page 7

- 34. Turner MR, et al., (2001) The King's data base 1990-2000:

  An analysis of the effect on survival of interventions in

  ALS. ALS and Other Motor Neuron Disorders, 2(Suppl. 2):43;
- 35. Vielhaber S, et al., (2000) Mitochondrial DNA abnormalities in skeletal muscle patients with sporadic amyotrophic lateral sclerosis. <a href="mailto:Brain"><u>Brain</u></a>, 123:1339-48 (Exhibit 20);
- 36. Wong PC, et al., (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron diseases characterized by vacuolar degeneration of mitochondria.

  Neuron, 14:1105-16; and
- 37. Youdim MBH, et al., (2001) Rasagiline (N-propargyl-1R(+)-aminoindan), a selective and potent inhibitor of mitochondrial monoamine oxidase B. <u>Br. J. Pharmacol.</u>, 132:500-6 (Exhibit 21).

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants :

Eran Blaugrund et al.

Serial No.:

10/712,958

Filed

November 13, 2003

Page 8

Pursuant to 37 C.F.R. §1.97(b), no fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

John P. White

Reg. No 28,678 Gary J. Gershik

Reg. No. 39,992

John P. White

Registration No. 28,678

Gary J. Gershik

Registration No. 39,992 Attorneys for Applicants Cooper & Dunham LLP

1185 Avenue of the Americas New York, New York 10036

(212) 278-0400

Form PTO-1449

**U.S. Department of Commerce** Patent and Trademark Office

Atty. Docket No. 67705/JPW/GJG/MML

Serial No. 10/772,958

Page 1 of 3

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Filing Date November 13, 2003

Applicants: Eran Blaugrund et al.

		_		<u> </u>					1 0.0.1717	TENT DOCUMENTS		7	7	
Examiner Initial		Dog	um	ent	Nu	mbe	r		Date	Name	Class	Subclass	Filing D	
				8	7	6	1	2	2/7/95	Youdim, et al.				
		5	4	5	3	4	4	6	9/26/95	Youdim, et al.;				
				5	7	1	3	3	10/10/95	Youdim,et al.;			1	
				6	8	1	8	1	9/16/97	Youdim, et al.;	_		ļ	
				7_	6	3	5	3	11/19/96	Youdim, et al.;			ļ	
			5	3	2	4	1_	5	7/2/96	Youdim, et al.;				
			_		9	9	9	1_	2/4/97	Youdim, et al.;				
				8	6	3	9	0	7/28/98	Youdim, et al.;				
		_	5	1	9	0	6	1	5/21/96	Youdim, et al.;				
				9	1	_	2	3	4/6/99	Youdim, et al.;				
		5	7		4_	5_	0	0	4/28/98	Youdim, et al.;	<u> </u>			
			3	_	6	5 .	0	4	2/7/95	Youdim, et al.;		<u> </u>		
		20	04	00	10	0_	3	8	1/15/04	Blaugrund et al.;				
						*	•		FOREIGN 1	PATENT DOCUMENT	`S			
		Document Number							Date	Country	Class	Subclass	Translation	
													Yes	No
	wo					0	5	+	9/4/2003	PCT;			ļi	
	wo	20	04	04	5	5	1_	5	6/3/04	PCT;				
			,											
•	<u></u>		0	THE	ER :	DO	CUI	ME	NTS (Includi	ng Author, Title, Date,	Pertinent I	Pages, Etc.)	2001	
									) A controlled )(9):585-91;	l trial of riluzole in amy	otrophic late	ral sclerosis. AL	S/Riluzo	le Stud
										ine Oxidase B Inhibitors	CNS Drug	s 6(3):217-36:		
		Deli	luc-	1 (1	00/	6) T	. al.,	hor	macalagy and	mechanism of action ril	uzole Neur	ology 47 (Suppl	1).5233	-41.
										ts (S) enantiomer increas			e in salt-le	oaded
		stro	ke-r	oron	e sı	ont	anec	ousl	y hypertensiv	e rats. J. Neural Transm.	<u>,108:909-23</u>	;		
	Ì									itrotyrosine and oxidativ	e damage ir	mice with a hur	nan copp	er/zind
		المديات	егох	ide	dis					eurol., 42:326-34;				
									. ,	tabolism/drug interaction	n studies – s	tudy design, dat	a analveis	
· · · · · · · · · · · · · · · · · · ·		"Gu	ıidaı	nce	for	Indu	stry	: In	vivo arug me	tabolishould interaction		tuuj uooigii, uui		i, and
У.		"Gu reco	idai mm	nce nend	for latic	Indu ons f	or d	losii	ng and labelir	g," U.S. Department of	Health and l	Human Services,	Food and	d Drug
χ.		"Gu reco Adr	idai omm nini	nce nend strat	for lation	Indu ons f	or d	losii for	ng and labelir Drug Evalua	ng," U.S. Department of Ition and Research (CDE	Health and l	Human Services,	Food and	d Drug
,		"Gu reco Adr Res	idai omm nini earc	nce nend strat ch (C	for lation CBE	Indu ons f i, Ce ER),	or d nter Nov	losii for vem	ng and labelir Drug Evalua ber 1999;	ng," U.S. Department of Ition and Research (CDE	Health and IR), Center f	Human Services, or Biologics Eva	Food and aluation a	d Drug nd
,	-	"Gu reco Adr Res Gur	idai omm nini earc	nce nend strat ch (C	for lation CBE	Induons for Ce ER),	or d nter Nov (19	losii for vem 94)	ng and labelir Drug Evalua ber 1999; Motor neuron	g," U.S. Department of	Health and IR), Center f	Human Services, or Biologics Eva	Food and aluation a	d Drug nd
		"Gu reco Adr Res Gur	idai omm nini earc	nce nend strat ch (C	for lation CBE	Induons for Ce ER),	or d nter Nov (19	losii for vem 94)	ng and labelir Drug Evalua ber 1999;	ng," U.S. Department of Ition and Research (CDE	Health and IR), Center f	Human Services, or Biologics Eva	Food and aluation a	d Drug nd
		"Gu reco Adr Res Gur	idai omm nini earc	nce nend strat ch (C	for lation CBE	Induons for Ce ER),	or d nter Nov (19	losii for vem 94)	ng and labelir Drug Evalua ber 1999; Motor neuron	ng," U.S. Department of Ition and Research (CDE	Health and IR), Center f	Human Services, or Biologics Eva	Food and aluation a	d Drug nd

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Eran Blaugrund et al. Serial No.: 10/712,958

Filed: November 13, 2003

Exhibit A

Page 2 of 3

Form PTO-	1449							it of Comme idemark Off	Atty. Dock		Serial No. 10/772,958					
INFORMATION DISC (Use several shee							. ~ -	OCHES CT	DA MIONI	Applicant	Applicants: Eran Blaugrund et al.					
										Filing Date Novembe						
								U.S. PAT	TENT DOCUMENTS							
Examiner Initial	Do	cum	ent l	Nui	nbe	r		Date	Name	Class	Filing Date if Appropriate					
		-			<u> </u>		<u> </u>					-				
			Н		-	$\vdash$	$\vdash$			_	1	<del> </del>				
		-	Н								<del> </del>	<del> </del>				
		_						FOREIGN I	PATENT DOCUMENT	rs						
	Do	cum	ent ]	Nui	mbe	r		Date	Country	Class	Subclass	Translation				
							_					Yes	No			
		_	$\sqcup$		<u> </u>	<u> </u>	_				ļ	<b>_</b>				
ļ <u> </u>		-	Н		-		-					+	<u> </u>			
l			$\Box$	L	<u> </u>	<u> </u>			ļ		1 .	<u> </u>	<u></u>			
	Hu aga Ko late Lat 31; Lat tre:	ang ninst ng J eral s comb	W, eclose, et a sclerolez  DJ, eclorolez  nt of	et all., (cosis L, et all f am	., (1 199 in in et al.	999 l inji 8) N mice ., (19	lasse ex	europrotectiv in the mouse sive mitochor pressing a mu ) Dose-rangin elegiline is incateral scleros	rol., 39:147-57; e effect of rasagiline, a s. Eur. J. Pharmacol., 336 ndrial degeneration in mutant SOD1. J. Neurosci. ng study of riluzole in an effective in a collaborati sis. Arch Neurol., 55(1): te therapy in ALS – whi	otor neurons ,18:3241-50 nyotrophic lave double-bl 93-6;	triggers the onso; ; ateral sclerosis. I	et of amy ancet, 34	otrophic 47:1425 ial for			
	pro	parè	gylar	nine	-1(	R)- a	and	(S)-aminoing	ns induce apoptosis in do dan, rasagiline and TV10 n-enforced bcl-2 overex	022. <u>J. Neura</u>	al Transm., 60(S	uppl):171	1-86;			
	ras	agili	ne, p	prev	ent	nuc	lear	accumulatio	n of glyceraldehyde-3-pl N-methyl(R)salsolinol. <u>J</u>	hosphate deh	ydrogenase indu	iced by a	n 			
								e (2002), p. 7								
	isc	hemi	ia in	the	rat.	J. N	leui	ral Transm., 1	sagiline, a monamine ox 106:593-606;							
	am Di:	yotro sorde	ophi ers, 2	c la 2(Su	tera ippl	l scl . 2):	ero: 43-	sis register ov 4;	prognosis in amyotroph ver a five year study peri	od 1995-200	00. ALS and Oth	er Motor				
									ata base 1990-2000: An Motor Neuron Disorders,			vival of				
EXAMINE	2							DATE CON	SIDERED							
									n is in conformance with MF		line through citatio	n if not in				

Page 3 of 3

Form PTO-1449 U.S. Departm Patent and T										Atty. Dock 67705/JP	cet No. W/GJG/MML	Serial No. 10/772,958		
	TAT	EAI	O N //	а ТТ	ON.	nic	CI	OSURE CI	ra TION	Applicant	s: Eran Blaugri	ınd et al		
	IIN							s if necessar		Filing Date Novembe	Filing Date November 13, 2003			
								U.S. PA	TENT DOCUMENTS					
Examiner Initial	Do	cum	ent	Nui	mbe	r	1	Date	Name	Class	Subclass	Filing Date if Appropriate		
			-	_	_	_	L					-		
	$\dashv$	<del> </del>	$\vdash$	<u> </u>	—		-					<u> </u>		
1								FOREIGN	PATENT DOCUMENT	'S				
	Do	cum	ent	Nui	mbe	r		Date	Country	Class	Subclass	Translation		
					1	_				<u> </u>		Yes	No	
		├	⊢	_	-	-	_		<u> </u>	- <del> </del>		<u> </u>		
			H			┢						1		
		1	┢╾	-	<del> </del> -	├	$\vdash$	·						
	_	<u> </u>	<u> </u>	<u> </u>	_	<u> </u>	<u> </u>				ļ	-		
		<u> </u>	Ŀ	<u> </u>	L	<u> </u>						<u> </u>	<u> </u>	
		lhat	рег 🤅	S, e	t al	., (2	200		ing Author, Title, Date, drial DNA abnormalitie 3:1339-48:			nts with	sporadio	
	Wo dis	ong l ease	PC, o	et al arac	., (1 teri:	995 zed \	) Ai	n adverse pro acuolar dege	perty of a familial ALS- eneration of mitochondria	ı. <u>Neuron,</u> 14	4:1105-16; and			
	Yo mit	udin och	n Mi ondr	BH, ial r	et a	d., (a oam	200 ine	1) Rasagiline oxidase B. <u>B</u>	: (N-propargyl-1R(+)-am <u>r. J. Pharmacol.</u> , 132:50	inoindan), a D-6.	selective and po	tent inhi	oitor of	
EXAMINER	<u>.                                      </u>							DATE CON	SIDERED			· ·		
+EV A BAINTED	. Inidial :	e air-			idor-	اري ام	h nel-		n is in conformance with MP	ED 600: Draw	line through citation	if not in		